2021 Wet Age Related Macular Degeneration (Wet - AMD) Pipeline Insight Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Wet Age - Related Macular Degeneration (Wet - AMD) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021," report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

SOK583A1: Sandoz

Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz. In May 2021, Sandoz announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT - a clinical Phase III confirmatory efficacy and safety study.

SB15: Samsung Bioepis

SB15 is being developed as a biosimilar to the reference product Eylea (aflibercept) - an anti-VEGF drug.

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Samsung Bioepis. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the US, Canada, Europe, Japan, and Australia.

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Wet Age-Related Macular Degeneration (Wet-AMD)

There are approx. 70+ key companies which are developing the Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.

Phases

This report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Current Scenario and Emerging Therapies:

• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Opthea Limited
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Kodiak Sciences
• Amgen
• Qilu Pharmaceuticals
• Xbrane Biopharma
• Regenxbio
• Formycon
• Dobecure
• Gemini Therapeutics
• Isarna Therapeutics
• AngioLab Inc
• Alkahest
• Tyrogenex
• IVERIC bio (formerly Ophthotech Corporation)
• Tasly Pharmaceutical Group
• Ribomic
• Innovent Biologics
• Gemini Therapeutics
• GrayBug Vision
• Curacle
• Quark Pharmaceuticals
• Bio-Thera Solutions
• RemeGen
• Sinocelltech
• PanOptica
• Clearside Biomedical
• AsclepiX Therapeutics
• Feramda
• AiViva BioPharma
• Unity Biotechnology
• Kyowa Kirin
• Ocular Therapeutix
• Janssen Research & Development
• Huabo Biopharm
• EyePoint Pharmaceuticals
• Shanghai Biomabs Pharmaceutical
• Ashvattha Therapeutics
• Samjin Pharm
• Akari Therapeutics
• Eyevensys
• PharmAbcine
• Neurophth Therapeutics
• Ocugen

Key Products

• SOK583A1
• SCD411
• SB15
• OPT-302
• LY09004
• HLX04-O
• GNR-067
• FYB203
• Faricimab
• CKD-701
• ONS-5010
• KSI-301
• ABP 938
• BCD 300
• Xlucane
• RGX-314
• FYB201
• Etamsylate
• GEM-103
• ISTH0036
• ALS-L1023
• AKST4290
• Vorolanib (X-82)
• Zimura
• Sanhuangjingshimingwan
• RBM-007
• IBI302
• GEM103
• GB-102
• CU03
• PF-04523655
• BAT5906
• RC 28 E
• SCT510A
• PAN 90806
• CLS-AX
• AXT107
• AS101
• AIV007
• UBX1325
• KHK4951
• OTX-TKI
• AAVCAGsCD59
• HB002.1M
• EYP-1901
• CMAB818
• D-4517
• SJP1803/1804
• Nomacopan
• EYS609
• EYS809
• PMC-309
• PMC-403
• NFS-10
• OCU 200

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v5kjx5

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900